Pillar 1 · The flagship

Blueprint Care

Your decision report, executed by a dedicated clinical team. Not a variant list, but the decision, the reasoning, the access routes and the people to carry it out.

Book a free consultation See the Signature tests

01The flagship

Your decision report, executed by a clinical team

Blueprint Care takes the complete molecular picture of your cancer and turns it into a ranked, sign-out-ready treatment plan. Then it puts a named clinical team beside you to act on it, monitor it, and adjust as things change.

It is fed by a Signature molecular test, or by your existing data through Decipher.

11decisions marked down

6intelligence layers

1signed plan

Page one of a Blueprint Care report on a desk, showing an Actionability Index of 9.2 out of 10, a first-line recommendation, the reasoning behind it, and the key molecular findings. — Page one: the Chief Oncologist Summary, built to be read in under a minute.

The questions a raw report cannot answer

A sequencing report says what mutations are present. Blueprint Care says what to do about them.

Which treatment should come first, and how confident is that call?
Which drugs are ruled out by this tumour’s biology?
Which recruiting trials match this exact profile?
Are there biosimilars or assistance programmes that make it affordable?
If the first line fails, what is the fallback and how will we know early?
Is there a hereditary signal that means my family should be tested?

Eleven things every Blueprint marks down

The same eleven decisions, every time, so nothing important is left implicit.

#	What we mark down	Why it matters
01	First-line therapy	The best-supported treatment to start, with a confidence rationale.
02	What to avoid	Therapies this tumour will resist, so time and money are not wasted.
03	Matched trials	Recruiting studies that fit this exact molecular profile.
04	Biosimilar options	Clinically equivalent, lower-cost alternatives available in India.
05	On-label vs off-label	Where a therapy is approved, and where it would be off-label or via trial.
06	Resistance plan	How the tumour may escape, and the serial testing to catch it.
07	Access and cost	Assistance programmes, schemes and a realistic out-of-pocket picture.
08	Hereditary flags	Signals that inherited risk testing is warranted for you and relatives.
09	Drug safety (PGx)	How you may metabolise key drugs, to dose safely and avoid harm.
10	Prognostic context	What the biology suggests, stated honestly and without false certainty.
11	Actionability Index	A single readout of how targetable this tumour is.

04Six section groups

Inside the report

The report moves from what to do in the next sixty seconds through to the deepest biology. It opens with a one-page Chief Oncologist Summary: the Actionability Index, what to start, what to avoid, and urgent flags.

Group	What it covers
Summary and actions	The clinical bottom line and a visual treatment roadmap.
Test provenance	What was sequenced, panel scope, limitations, pipeline traceability.
Genomic landscape	TMB, MSI, mutational signatures and the copy-number picture.
Clinical variants	Every driver alteration, its evidence tier and its consequence.
Intelligence layers	Subtype, clonal architecture, immune evasion, synergy, pathway biology.
Therapy and access	Therapy matrix, immunotherapy index, trials, resistance forecast, India access.

Diagram placeholder

Report anatomy, exploded

What goes here: Illustrated diagram of the report broken into its six groups as stacked layers, with the Chief Oncologist Summary floating on top. Annotate which reader each layer serves: the treating oncologist in sixty seconds, the tumour board in depth, the patient in plain language. Brand purple layers, mint callouts.

05Beyond public databases

Six intelligence layers

Public annotation tells you what a variant is. These layers tell you what to do about it.

CloneTrace™clonal architecture

Which mutations are founder events present in every cancer cell, and which are later branches, so therapy targets the trunk rather than a twig.

SynerGx™combination synergy

Which drug combinations offer real added benefit versus overlapping toxicity, scored as a net-benefit index.

PhenoMap™molecular subtype

The tumour’s biological subtype, which sharpens both treatment choice and prognosis.

ImmunoLens™immune readiness

Whether the immune system can see the tumour, combining antigenicity with intact antigen presentation, to predict immunotherapy response.

TrialGraph™trials and cohorts

Recruiting trials that fit this profile, plus a real-world picture of similar patients.

AccessMatch™access and economics

Biosimilars, assistance programmes and the realistic cost pathway in India.

The eight-step journey

Step 1Free consultation
We choose the right starting test, or use your existing data.
Step 2Sample
A blood draw at home or in clinic, or your existing tissue block.
Step 3Sequencing
An accredited laboratory reads the DNA with transparent quality control.
Step 4Engine
Annotation, matching, and the six intelligence layers.
Step 5KPCIRC sign-out
A molecular tumour board authors and signs the plan.
Step 6Your report
The full document plus a plain-language version in your language.
Step 7Navigator sessions
Someone walks you and your family through results and access.
Step 8Continue
Sentinel, Clear and Heritage extend the same care.

Video placeholder

Meet your navigator

What goes here: Two-minute piece featuring a real OnKommon navigator. They explain, in first person, what they actually do in a week: chasing a tumour block, filing assistance paperwork, sitting with a family after a result. Filmed on location, not in a studio. This is the most reassuring asset on the site, so make it feel like meeting a person.

Three ways in

Blood

A simple draw. No surgery, repeatable, ideal when tissue is hard to get. See the blood tiers.

Tissue

If you have a tumour block, Signature STt O profiles it comprehensively.

Existing data

Already tested elsewhere? Decipher builds the full report from your results, with no resequencing.

What the relationship includes

A dedicated navigator and in-person sessions.
Your report in your regional language, written for you and your family.
A clear management timeline so you know what happens next.
Genetic counselling through KPCIRC where hereditary risk is flagged.
Financial navigation: biosimilars, assistance programmes and schemes.
Second opinions on demand, provided by KPCIRC on a paid basis.

Standard report vs Blueprint Care

	Blueprint Care	A standard report
Output	Ranked, signed decision and plan	A variant list
Interpretation	Six proprietary intelligence layers	Left to the reader
Accountability	KPCIRC licensed sign-out	Often unclear
Trials and biosimilars	Matched and marked down	Rarely included
India cost pathway	Assistance programmes and schemes surfaced	Not addressed
Language	Plus a regional-language summary	Technical English
Afterwards	A navigator and continuous coordination	You are on your own

Built for India

Precision oncology is only real if you can reach it. We pair expensive targeted therapies with CDSCO-approved biosimilars where clinically equivalent, file the paperwork for assistance programmes, and map state and private schemes.

Pricing and sign-out

Included with your test not sold separately

Blueprint Care is the decision report and the continuing clinical relationship that come with every Signature test or Decipher. Your consultation confirms which test feeds it and the total.

Research and evidence

The science behind this

Comprehensive profiling reviewed by a molecular tumour board has been studied in thousands of patients.

Study 1

Tumour board review improved outcomes

In 715 patients with advanced cancer, closer matching between therapy and molecular profile on board advice gave better response and longer survival.

Kato S, et al. Nature Communications, 2020.

Study 2

Higher matching, better results

In treatment-refractory cancers, patients whose therapy targeted more of their specific alterations had significantly longer progression-free and overall survival.

Sicklick JK, et al. (I-PREDICT) Nature Medicine, 2019.

Study 3

What the overall evidence shows

A systematic review found board review appears to improve outcomes, while calling for more prospective randomized trials.

Systematic review, JCO Precision Oncology, 2021.

These independent, peer-reviewed studies describe the class of technology we use. They are shared for education. They are not results for any individual and not a promise of benefit.

Being clear about our limits

What we do and do not do

What we DO

Turn results into a ranked, signed treatment plan
Match your profile to therapies, trials and biosimilars in India
Give you a named navigator and a regional-language summary
Provide serial monitoring to follow the plan over time

What we DON’T do

Diagnose cancer or prescribe medicines
Guarantee a drug will be available, approved, covered or effective
Replace your oncologist or the tumour board sign-out
Act as an emergency service

Plain-language glossary (6 terms)

Term	What it means
MTB	Molecular tumour board, the specialist panel that signs your plan.
CGP	Comprehensive genomic profiling, reading many cancer genes in one test.
TMB	Tumour mutational burden, how many mutations a tumour carries.
MSI / MMR	Signals of faulty DNA repair that often predict immunotherapy response.
ctDNA	Circulating tumour DNA, tumour fragments a blood test can read.
Actionable	A finding with a matched drug, a trial, or a clear management step.

Important information and regulatory status

Blueprint Care and the Signature tests that feed it is a genomic (DNA-based) test for use by qualified healthcare professionals. It supports clinical judgement, it does not replace it, and it must be read alongside your full clinical history and applicable guidelines.

A result is not a diagnosis and does not by itself decide treatment.
A “not detected” result does not rule out cancer or a genetic change.
Not all cancers release enough DNA into blood to be detected.
We cannot guarantee that a medicine will be available, approved, covered or effective.
Collection kits are for qualified phlebotomists. They are not for self-testing.
Confirmatory testing may be required.

Regulatory status (India). Registration of our genomic tests as in-vitro diagnostic (IVD) medical devices with CDSCO is in progress, with the IVD class pending. Sequencing and variant calling are done by an accredited laboratory partner (CAP-accredited, ISO 15189) following ACMG/AMP/ASCO/CAP guidelines and a CE-IVD certified variant database. The OnKommon interpretation engine is provided for research and decision-support use. Marketing follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.

Take the next step

Three ways forward. Pick the one that fits today.

Book a free consultation

A no-obligation conversation with our care team, arranged through KPCIRC.

Book a consultation

Begin Blueprint Care

Commission your decision report and a dedicated clinical team.

Explore Blueprint Care

Ask on WhatsApp, free

Signal replies to your first question within four hours, at no cost.

Start with Signal